Robert Holmes, MD
Gastroenterology · Winston-Salem, NCNPI 1306803234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.
Across 246 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$965
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$662
- Johnson & Johnson$579
- Takeda Pharmaceuticals U.S.A., Inc.$461
- Fujifilm Healthcare Americas Corporation$241
- Gilead$183
- plus $2K from 29 others
Across 143 payments — averaging $2424.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$111K
- Teva Pharmaceuticals USA, Inc.$88K
- Ironwood Pharmaceuticals, Inc$68K
- Bristol Myers Squibb$42K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Adare Pharmaceuticals, Inc.$4K
- plus $6K from 2 others
What the payments were for
- Food & beverage$4,31293%
- Education$992%
- Gifts$1503%
- Other$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $965 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $662 |
| Johnson & Johnson | 27 | $579 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $461 |
| Fujifilm Healthcare Americas Corporation | 6 | $241 |
| Gilead | 11 | $183 |
| Pfizer | 10 | $154 |
| Bristol Myers Squibb | 9 | $150 |
| Merck | 6 | $97 |
| QOL Medical, LLC | 7 | $90 |
| Intercept Pharmaceuticals, Inc. | 5 | $86 |
| Organon | 3 | $77 |
| Sanofi | 4 | $77 |
| UCB, Inc. | 5 | $75 |
| Ironwood Pharmaceuticals, Inc | 5 | $74 |
| Ardelyx, Inc. | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Redhill Biopharma Inc. | 1 | $53 |
| Shionogi Inc | 3 | $51 |
| Braintree Laboratories, Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Amgen(2 entities) | 2 | $39 |
| AstraZeneca | 2 | $38 |
| Lilly USA, LLC | 2 | $30 |
| Shire North American Group Inc | 2 | $28 |
| Intra-sana Laboratories | 2 | $28 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Mylan Institutional Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Invivyd Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,652 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 34 | $472,377 |
| ZenpepLipase/Protease/Amylase | 30 | $59,255 |
| LinzessLinaclotide | 22 | $14,771 |
| CreonLipase/Protease/Amylase | 13 | $9,875 |
| MotegrityPrucalopride Succinate | 12 | $9,193 |
| Colestipol Hcl | 44 | $4,718 |
| Omeprazole | 207 | $4,171 |
| Mesalamine | 16 | $3,418 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 17 | $2,745 |
| Mercaptopurine | 36 | $2,744 |
| Pantoprazole Sodium | 203 | $2,528 |
| Budesonide EcBudesonide | 19 | $1,497 |
| Codeine Sulfate | 11 | $1,481 |
| Ursodiol | 13 | $1,445 |
| Dicyclomine Hcl | 46 | $1,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $965 | $24,64535 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $461 | $9,19312 claims |
| Braintree Laboratories, Inc.Sutab | $48 | $2,74517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Winston-Salem
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
- Manal AbdelmalekDurham$402K
- Christopher McGowanCary$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.